Gapping up
In reaction to strong earnings/guidance: GBX +1.8%,
STZ +1.3%
M&A news: BUD +2.8% (increases offer to acquire SABMiller (SBMRY) for GBP42.15 per share),
CYBR +1.4% (acquires privately held Viewfinity for $30.5 mln in cash; expected to be accretive to non-GAAP EPS for 2016)
Select China related names showing strength: SOHU +3.4%,
CMCM +3%,
WYNN +2.4%,
YY +2.1%,
QIHU +2.1%,
HSBC +2%,
WUBA +2%,
YNDX +1.7%
Select metals/mining stocks trading higher: MT +8.6%,
HMY +5.4%,
BBL +4.2%,
BHP +3.8%,
FCX +3.3%,
AU +3.1%,
VALE +3.1%,
GOLD +2.9%,
X +2.8%,
AKS +2.5%,
AA +1.9%
Select oil/gas related names showing strength: SDRL +5.9%,
SD +4.8%,
SSL +4.3%,
BP +4.1%,
DNR +3.9%,
PBR +3.7%,
TOT +3.5%,
RIG +2.8%,
RDS.A +2.7%,
NE +2.5%,
CHK +1.9%,
COP +1.5%
Other news: MDCO +8.4% (co and SymBio Pharmaceuticals established a strategic partnership for IONSYS in Japan),
DERM +5% (presents DRM01 Phase 2a trial data, showing the topline met all primary efficacy endpoints),
CANF +3.6% (to deliver 2 presentations on its cancer drug CF102 on Oct 8-10 in Athens),
AMRI +3% (extended Supply Agreement with GE Healthcare),
CDE +2.5% (reported preliminary Q3 production of 3.8 mln ounces of silver and 85,658 ounces of gold, or 9.0 mln silver equivalent ounces; maintained FY15 production guidance),
LINE +1.9% ( Linn Energy and LinnCo announces Board approval to suspend the companies' distribution and dividend, effective September 30, 2015),
CLF +1.7% ( Terminates Pellet Supply Agreement with Essar Algoma ),
EXAS +1.7% (modestly rebounding following yesterday's sell off),
TWTR +1.4% (Prince Alwaleed Bin Talal discloses 5.17% passive stake in 13G filing),
EXC +1.3% (late move higher on reports of DC announcement),
POM +1.3% (late move higher on reports of DC announcement),
PFE +1.3% (Pfizer and Merck KGaA (MKGAY) granted Fast Track designation by the FDA for avelumab for the treatment of metastatic Merkel cell carcinoma)
Analyst comments: RIO +8.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley),
BHP +3.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley),
CTRP +3.1% (upgraded to Buy from Neutral at BofA/Merrill),
MPC +2.3% (upgraded to Outperform from Market Perform at Wells Fargo),
UBS +1.6% (upgraded to Buy at BofA/Merrill),
MS +1.2% (upgraded to Outperform at RBC Capital Mkts)